Imjudo
Payments companies reported to CMS as associated with Imjudo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Imjudo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Imjudo
These are the largest totals companies reported as associated with Imjudo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ferdinandos Skoulidis | Houston, TX | Medical Oncology | $4,591.09 |
| Farshid Dayyani | Orange, CA | Medical Oncology | $4,192.20 |
| Uqba Khan | Brooklyn, NY | Hematology & Oncology | $2,808.50 |
| Hossein Borghaei | Philadelphia, PA | Magnetic Resonance Imaging (Mri) | $2,660.00 |
| Ilyas Sahin | Boston, MA | Hematology (Internal Medicine) | $2,397.50 |
| Aram Hezel | Rochester, NY | Hematology & Oncology | $2,397.50 |
| Gina Vaccaro | Cookeville, TN | Medical Oncology | $2,397.50 |
| Saira Khaderi | Houston, TX | Transplant Hepatology | $2,325.00 |
| Arturo Loaiza-Bonilla | Pennington, NJ | Hematology & Oncology | $2,274.20 |
| Matthew Dugan | Westbrook, ME | Hematology & Oncology | $2,258.85 |
Prescribed Imjudo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.